Abstracts tagged "quality of life"

Abstract Number: 059 • 2020 Pediatric Rheumatology Symposium
Challenges Faced by Families of Children with an Auto-inflammatory Disease
Lori Tucker¹, Maria Belen ², Jenny Tekano ², Iwona Niemietz ³, Martina Sundqvist ³ and Kelly Brown ³, ¹BC Children's Hospital, Vancouver, British Columbia, Canada, ²BC CHildren's Hospital, Vancouver, Canada, ³BC Children's Hospital Research Institute, Vancouver, Canada
Background/Purpose: Auto-inflammatory diseases (AIDs) are rare disorders that usually present in young children. Disease episodes, characterized by recurrent inflammation, are often frequent and unpredictable, and…
Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium
Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Lauren Ambler¹, Rula Issa ², Stephanie Pan ² and Rebecca Trachtman ², ¹Mount Sinai Hospital, New York, ²Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
Abstract Number: 104 • 2020 Pediatric Rheumatology Symposium
Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life
Mariana Correia Marques¹, Nicole Tennermann ², Sivia Lapidus ³, Grant Schulert ⁴, Jennifer Tousseau ², Rashmi Sinha ⁵, Karen Durrant ⁶, Saskya Angevare ⁷ and Fatma Dedeoglu ⁸, ¹Boston Children's Hospital, Boston, Massachusetts, ², ³The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood, ⁴Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, ⁵Systemic JIA Foundation, Cincinnati, ⁶Autoinflammatory Alliance, San Francisco, ⁷Amersfoort, Netherlands, ⁸Boston Children's Hospital, Boston
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) encompass multiple clinical entities in which spontaneous inflammation occurs due to dysregulation of the innate immune response. The variability in…
Abstract Number: 117 • 2020 Pediatric Rheumatology Symposium
Family Impact of Juvenile Localized Scleroderma
Katia Milovanova¹, Vimal Prajapati ², Merna Adly ², Rebeka Stevenson ³, Brendan Lethebe ² and Nadia Luca ², ¹University of Alberta, Edmonton, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Cochrane, Alberta, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare autoimmune disease that can lead to significant morbidity. Previous studies have focused on predictors of patient health-related…
Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Sofia Soukka ¹, Alvaro Gomez ¹, Yvonne Enman ¹, Petter Johansson ¹, Sharzad Emamikia ¹ and Katerina Chatzidionysiou ¹, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…
Abstract Number: 2702 • 2019 ACR/ARP Annual Meeting
Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group
Alessandra Alongi¹, Serana Calandra ¹, Susan Thornhill ², Jennifer Stinson ³, Jen Horonjeff ⁴, Daniel Horton ⁵, Alessandro Consolaro ⁶ and Esi Morgan ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ²Thornhill Associates, Hermosa Beach, USA, Hermosa Beach, ³The Hospital for Sick Children, and University of Toronto, Toronto, Canada, Toronto, ⁴Columbia University Medical Center, New York, USA, New York, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis Core Set Working Group formed in 2015 as an international initiative to revise the existing Core Set with relevant…
Abstract Number: 2765 • 2019 ACR/ARP Annual Meeting
Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis
Matt Allsion¹, Michael McMorris ², Dhiren Patel ² and B Stephen Burton ³, ¹Pack Health, Birmigham, AL, ²Pack Health, Birmingham, ³Pack Health, Birmingham, AL
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. RA has a significant negative impact on the ability to perform daily…
Abstract Number: 247 • 2019 ACR/ARP Annual Meeting
Health Literacy, Adherence, and Quality of Life of Uveitis Patients
Claire Mueller ¹ and Ghazala O'Keefe¹, ¹Emory University School of Medicine, Atlanta, GA
Background/Purpose: To determine health literacy, medication adherence, and quality of life (QOL) of uveitis patients in order to understand how to deliver better and improved…
Abstract Number: 416 • 2019 ACR/ARP Annual Meeting
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Josep Verges¹, Marianna Vitaloni ¹, Rosa Sciortino ², Maritza Quintero ², Marco Bibas ¹, Jordi Monfort ³, Francisco de Abajo ⁴, Marco Matucci-Cerinic ⁵, Patrick du Souich ⁶, Ingrid Möller ⁷, Guy Eakin ⁸ and Angie Botto-van Bemden ⁸, ¹Osteoarthritis International Foundation, Barcelona, Spain, ²De los Andes University, Merida, Venezuela, ³Hospital del Mar, Barcelona, Spain, ⁴Universidad de Alcalá, Madrid, Spain, ⁵University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Arthritis Foundation, Atlanta
Background/Purpose: Knee OA (KOA) associates with remarkable functional restrictions due to pain that seriously affect social and emotional well-being, reducing the quality of life (QoL).…
Abstract Number: 422 • 2019 ACR/ARP Annual Meeting
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
Vibeke Strand¹, Pankaj Patel ², Naijun Chen ² and Elizabeth M Lesser ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago
Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
Abstract Number: 428 • 2019 ACR/ARP Annual Meeting
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
Srita Chakka¹, Rebecca Krain ¹, Sarah Ahmed ², Josef Concha ¹, Rui Feng ³ and Victoria Werth ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA
Background/Purpose: To date, there are no approved treatments for cutaneous lupus erythematosus (CLE), a disease known to significantly burden a patient’s quality of life (QoL).…
Abstract Number: 557 • 2019 ACR/ARP Annual Meeting
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey
Theresa Hunter¹, David Sandoval ², Nicola Booth ³, Elizabeth Holdsworth ⁴ and Atul Deodhar ⁵, ¹Eli Lilly and Company, Indianapolis, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Manchester, England, United Kingdom, ⁵Oregon Health & Science University, Portland, OR
Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
Abstract Number: 1120 • 2019 ACR/ARP Annual Meeting
Prevalence of Burnout in Rheumatology Professionals
Vivekanand Tiwari¹, Arthur Kavanaugh ², George Martin ³ and Martin Bergman ⁴, ¹Temple University, Philadelphia, PA, ²University of California, San Diego School of Medicine, La Jolla, CA, ³Dr. George Martin Dermatology Associates, Kihei, HI, ⁴Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Burnout among physicians has major implications for health care. We measured prevalence of burnout in a large group of Rheumatology professionals attending a national…
Abstract Number: 1258 • 2019 ACR/ARP Annual Meeting
Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial
John Reveille¹, Atul Deodhar ², Diane Harrison ³, Elizabeth Hsia ⁴, Eric K H Chan ³, Shelly Kafka ⁵, Kim Hung Lo ³, Lilianne Kim ³ and Chenglong Han ³, ¹University of Texas McGovern Medical School, Houston, ²Oregon Health & Science University, Portland, OR, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: In patients with ankylosing spondylitis (AS), IV administration of the anti-TNFa antibody golimumab (GLM-IV) resulted in improvements in composite measures of various aspects of…
Abstract Number: 1466 • 2019 ACR/ARP Annual Meeting
Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome
Naoto Azuma¹, Yoshinori Katada ², Aki Nishioka ³, Masahiro Sekiguchi ⁴, Masayasu Kitano ⁵, Sachie Kitano ¹, Hajime Sano ⁶ and Kiyoshi Matsui ¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology, Sakai City Medical Center, Sakai, Japan, ³Department of Rheumatology, Nishinomiya Watanabe Hospital, Nishinomiya, Japan, ⁴Departement of Rheumatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan, ⁵Department of Rheumatology, Kyoto Okamoto Memorial Hospital, Kumiyama, Japan, ⁶Kyoto Okamoto Memorial Hospital, Kumiyama, Japan
Background/Purpose: In addition to xerostomia symptoms, patients with Sjögren’s syndrome (SS) experience pain and discomfort in the oral cavity, and difficulties in speaking and eating,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].